Latest Breaking News On - Novartis pharmaceuticals corporation - Page 6 : comparemela.com

Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

United statesUniversity of minnesotaOrange countyMatthew meiCitius pharmaMyron czuczmanIlanit allenGreg salsburgVeronika bachanovaLos angelesUniversity of minnesota masonic cancer centerMasonic cancer centerPrnewswire citius pharmaceuticals incExchange commissionNovartis pharmaceuticals corporationCancer center

Citius Pharmaceuticals, Inc : Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals, Inc : Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUniversity of minnesotaOrange countyLos angelesIlanit allenMyron czuczmanMatthew meiVeronika bachanovaGreg salsburgDennis riedlCitius pharmaKite pharma incUniversity of minnesota masonic cancer centerCompany nasdaqSecurities exchangeTranslational genomics research institute

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

United statesSouth koreaNoord hollandMichael meoMarlena abdinoorMichael korenParag mahantiJonathan grahamSloan simpsonColl cardiolHealth promotion seriesAlnylam pharmaceuticalsAmerican heart associationEuropean medicines agencyNovartis pharmaceuticals corpAmerican college of cardiology congress

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on.

South koreaNoord hollandUnited statesMichael korenSloan simpsonPrnewswire novartisMarlena abdinoorJonathan grahamParag mahantiColl cardiolMichael meoNovartis pharmaceuticals corpWorld health organizationEuropean medicines agencyEuropean society of cardiology congressWorld heart federation

The Multiple Sclerosis Association of America (MSAA) Selects SEQSTER to Accelerate Patient-Centricity & Innovation

SAN DIEGO (BUSINESS WIRE) Mar 22, 2024

San diegoUnited statesCherry hillDiana cruzBill douglassGina ross murdochMariae fernandezLeorah freemanPopulation healthSclerosis association of americaSclerosis implementation networkNeuroimmunology centerUthealth houston school of public healthUt health austinCommunications marketing departmentDell medical school